Zobrazeno 1 - 10
of 12
pro vyhledávání: '"929"'
Autor:
Jinsuk Kang
Publikováno v:
Cancer Research. 81:929-929
STAT3 functions are largely bifurcated: (1) STAT3 activated by Y705 phosphorylation (pY705) regulates target-gene expression in nucleus. (2) STAT3 activated by S727 phosphorylation (pS727) supports a electron transport complex (ETC) in mitochondria.
Autor:
Oscar Arrieta, R. Bernabé, Judith Dalmau, Miguel Angel Molina-Vila, Jorge Carrillo, Remedios Blanco, Teresa Moran, Clara Mayo de las Casas, Jillian Wilhelmina Paulina Bracht, Bonaventura Clotet, Christian Brander, Jordi Argilaguet, Julia G. Prado, Mariano Provencio, Javier Garcia-Corbacho, Ana Giménez-Capitán, Mónica Garzón, Erika Aldeguer, Andrés F. Cardona, Rafael Rosell, Bartomeu Massuti, Javier de Castro, Maria Gonzalez-Cao, Javier Martinez-Picado, Andreas Meyerhans, Sonia Rodríguez, Oscar Juan, Ana Drozdowskyj, Chung-Ying Huang, J. Blanco
Publikováno v:
Cancer Research. 80:929-929
Introduction: Treatment with anti PD-1/PD-L1 antibodies has demonstrated clinical activity in different types of solid tumors, but only 20 to 30% of patients (pts) respond to these immune checkpoint inhibitors (ICIs). Therefore, predictive biomarkers
Autor:
Carol Thach, Jeff Kucharski, Jingchuan Zhang, Yvonne Yao, Shuangwei Li, Anjali Babbar, Dashyant Dhanak, Rasmus Hansen, Yuan Liu, Yuching Chen, Pingda Ren, Ulf Peters, Yi Liu, Shisheng Li, Ke Yu, Yi Wang, Patrick Parvis Zarrinkar, Xiaohu Deng, Matthew R. Janes, Sarah J. Firdaus, Ata Zarieh, Lian-Sheng Li, Tao Wu, Xin Guo, Jun Feng, Matthew V. Lorenzi, Dana D. Hu-Lowe, Jeffrey H. Chen
Publikováno v:
Cancer Research. 78:929-929
Activating mutations in KRAS have a high prevalence in human cancer. The codon 12 glycine to cysteine missense mutation (KRASG12C) is among the most common KRAS mutations, present in non-small cell lung adenocarcinoma (~15 %), colorectal adenocarcino
Autor:
Max S. Wicha, Michael D. Brooks
Publikováno v:
Cancer Research. 77:929-929
The CSC hypothesis posits that there is a subset of tumors cells driving tumor growth and metastasis and that by targeting this population, tumors can be more efficiently eradicated. Recently it was shown that there are two types of CSCs in breast ca
Autor:
Timothy P. Kuka, Jason B. Bell, Branden S. Moriarity, Vincent W. Keng, David A. Largaespada, Barbara R. Tschida
Publikováno v:
Cancer Research. 74:929-929
The role of zinc finger and BTB domain containing 20 (ZBTB20) in hepatocellular carcinoma (HCC) is not well defined, as there are many discrepancies in the literature regarding its role in liver tumorigenesis. ZBTB20 has been implicated to play a rol
Autor:
Noopur Shah, Fang Liu, Hubert Maehr, Amanda K. Smolarek, Milan R. Uskokovic, Jae Young So, Nanjoo Suh
Publikováno v:
Cancer Research. 72:929-929
CD44, a transmembrane glycoprotein, is highly expressed in breast tumors, and the overexpression of CD44 has been associated with poor clinical outcome. CD44 has been known to play a key role in invasive growth of cancer by interacting with extracell
Autor:
Susanne M. Hooshmand, David C. Christiani, Xihong Lin, Rihong Zhai, Kofi Asomaning, Matthew H. Kulke, Chen-yu Liu, Zhaoxi Wang, Christine Frauenhoffer, Li Su, Monica Ter-Minassian
Publikováno v:
Cancer Research. 70:929-929
BACKGROUND: Genetic risk factors for sporadic neuroendocrine tumors remain poorly understood. To identify genetic variants associated with neuroendocrine tumor risk, we first performed a large-scale assessment of common genetic variants in candidate
Autor:
Bradley M. Turner, Danielle E. Desa, Edward B. Brown, Brandon Buscaglia, Robert L. Strawderman, Robert L. Hill, David G. Hicks
Publikováno v:
Cancer Research. 79:P6-09
Background: Over-expression of Human Epidermal Growth Factor receptor-2 (HER2) in breast cancer is associated with an aggressive clinical course and poor prognosis. Targeting HER2 over-expression has been shown to be a remarkably effective therapeuti
Publikováno v:
Cancer Research. 79:P1-10
Background: Type II diabetes (T2D) has been found to modestly (10-20%) increase risk for breast cancer (BC) in mostly white populations. Some studies indicate that this association varies by BC receptor subtype, suggesting that T2D increases risk spe
Autor:
Romualdo Barroso-Sousa, Priti Kumari, Andrew D. Cherniack, Alice H. Berger, Deborah A. Dillon, Ethan Cerami, EP Winer, Ian E. Krop, Neal I. Lindeman, N Wagle, Ana C. Garrido-Castro, Melissa E. Hughes, Brittany L. Bychkovsky, S Di Lascio, H Guo, Nu Lin, Laura E. MacConaill, Janet Files, Elizabeth A. Mittendorf
Publikováno v:
Cancer Research. 79:PD9-01
Background: Discordance in hormone receptor (HR) status between primary (p) tumors and metastatic (m) recurrences has been widely described. Loss of estrogen and progesterone receptor expression occurs in ˜12% of asynchronous recurrences, leading to